. Author manuscript; available in PMC: 2022 Oct 5.

Published in final edited form as: Clin Cancer Res. 2020 Dec 7;27(9):2378–2382. doi: 10.1158/1078-0432.CCR-20-3901

Table 1:

Summary of Condition and Available Therapies

Disease	Current Treatment Options
Metastatic SCLC	First-line treatment for patients with newly diagnosed ES-SCLC, including metastatic SCLC, consists of platinum-based chemotherapy with FDA-approved immunotherapy (atezolizumab or durvalumab) (ref 6, 7). Second-line treatment options include: • Retreatment with a platinum-based regimen (for patients with recurrence >6 months from last dose of platinum) or use of single-agent chemotherapy. • Topotecan is the only FDA-approved therapy for patients with recurrent or progressive SCLC, specifically for patients with platinum-sensitive disease (9). Prior to lurbinectedin, there was no approved therapy for patients with platinum-resistant disease that has no response to or disease progression after first-line chemotherapy.

Disease

Current Treatment Options

Metastatic SCLC

First-line treatment for patients with newly diagnosed ES-SCLC, including metastatic SCLC, consists of platinum-based chemotherapy with FDA-approved immunotherapy (atezolizumab or durvalumab) (ref 6, 7).
Second-line treatment options include:
• Retreatment with a platinum-based regimen (for patients with recurrence >6 months from last dose of platinum) or use of single-agent chemotherapy.
• Topotecan is the only FDA-approved therapy for patients with recurrent or progressive SCLC, specifically for patients with platinum-sensitive disease (9).
Prior to lurbinectedin, there was no approved therapy for patients with platinum-resistant disease that has no response to or disease progression after first-line chemotherapy.

Data from the following sources:

Drug Approval Package: TECENTRIQ (atezolizumab). Drugs@FDA [database on the Internet]. Silver Spring (MD): U.S. Food and Drug Administration. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761034 (ref. 6)

Drug Approval Package: IMFINZI (durvalumab). Drugs@FDA [database on the Internet]. Silver Spring (MD): U.S. Food and Drug Administration. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process (ref. 7)

Drug Approval Package: HYCAMTIN (topotecan). Drugs@FDA [database on the Internet]. Silver Spring (MD): U.S. Food and Drug Administration. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020671 (ref. 9)